NCT04691570Phase 2Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ANX005 in Participants With Warm Autoimmune Hemolytic Anemia (wAIHA)

Study sponsor: Annexon, Inc. · ANNX

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2023-01-17Actual
Enrollment · participants7Actual
Source updated2026-06-30Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 2 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Safety: Treatment-emergent adverse events (TEAEs) Measure: Change in disease activity biomarkers. After: Measure: Number of Participants With Treatment-emergent Adverse Events (TEAEs) Measure: Maximum Change From Baseline in Hemoglobin Levels Measure: Change From Baseline in Lactate Dehydrogenase Levels at Day 71 Measure: Change From Baseline in Percentage of Reticulocytes/Total Cells Count at Day 71 Measure: Change From Baseline in Haptoglobin Levels at Day 71 Measure: Change From Baseline in Total Bilirubin Levels at Day 71 Measure: Change From Baseline in Indirect Bilirubin Levels at Day 71.

Actual enrollment increased by 1 participants

Before: 6 participants (actual). After: 7 participants (actual).

Check registry source